Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Aptamer Group o.325p £6.47m (APTA.L) The developer of next-generation synthetic binders delivering innovation to the life science industry has entered into a global licensing agreement with the University of Glasgow.</li>
<li>The Agreement is for the commercial use of its Optimer binders as vaccine adjuvants in the swine health sector.</li>
<li>The University will lead product development; commercialisation is anticipated within the next 12 months.</li>
</ul>


Aptamer Group o.325p £6.47m (APTA.L) The developer of next-generation synthetic binders delivering innovation to the life science industry has entered into a global licensing agreement with the University of Glasgow.
The Agreement is for the commercial use of its Optimer binders as vaccine adjuvants in the swine health sector.
The University will lead product development; commercialisation is anticipated within the next 12 months.


<ul>
<li>Abingdon Health 6.25p £11.71m (ABDX.L) The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech announces that, further to its announcement yesterday, it has completed and closed the placing to raise gross proceeds of £3.3m.</li>
<li>As part of the Placing, Chris Hand, Executive Chairman of the Company, has agreed to subscribe for £30k.</li>
<li>In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at the Placing Price, to raise up to £200k. </li>
</ul>


Abingdon Health 6.25p £11.71m (ABDX.L) The international developer, manufacturer and regulatory services provider for rapid diagnostic tests and medtech announces that, further to its announcement yesterday, it has completed and closed the placing to raise gross proceeds of £3.3m.
As part of the Placing, Chris Hand, Executive Chairman of the Company, has agreed to subscribe for £30k.
In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at the Placing Price, to raise up to £200k. 


Sosandar PLC - Hybridan Small Cap Feast: 14/10/2025

<ul>
<li>1Spatial Holdings 53.0p £60.87m (SPA.L) The global Location Master Data Management software and solutions provider reports Interims to July.</li>
<li>Revenue increased 9% to £17.7m with a 50% increase in SaaS Term licenses to £0.8m and ARR grew 11.9% to £19.1m.</li>
<li>The is EBITDA improved to £2.1m from £2m, while the LBT increased to £0.3m from £0.2m. </li>
</ul>


1Spatial Holdings 53.0p £60.87m (SPA.L) The global Location Master Data Management software and solutions provider reports Interims to July.
Revenue increased 9% to £17.7m with a 50% increase in SaaS Term licenses to £0.8m and ARR grew 11.9% to £19.1m.
The is EBITDA improved to £2.1m from £2m, while the LBT increased to £0.3m from £0.2m. 


<ul>
<li>Angle 2.20p £8.87m (AGL.L) The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and clinical oncology revises its business strategy.</li>
<li>The Chairman, Dr Jan Groen, has moved into an executive role to lead the Company as it focuses on tight cost control, accelerated commercial progress, and a clear plan towards becoming a sustainable business.</li>
<li>As part of its revised strategy, the Company proposes to change its name to Ce1LBxHealth plc to reflects the sharpened focus on the provision of high-value CTC-based precision diagnostic testing. </li>
</ul>


Angle 2.20p £8.87m (AGL.L) The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and clinical oncology revises its business strategy.
The Chairman, Dr Jan Groen, has moved into an executive role to lead the Company as it focuses on tight cost control, accelerated commercial progress, and a clear plan towards becoming a sustainable business.
As part of its revised strategy, the Company proposes to change its name to Ce1LBxHealth plc to reflects the sharpened focus on the provision of high-value CTC-based precision diagnostic testing. 


Xeros Technology Group Plc - Hybridan Small Cap Feast: 08/10/2025

<ul>
<li>1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.</li>
<li>There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.</li>
<li>The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. </li>
</ul>


1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.
There is a 3% increase in revenue to £33.4m of which 62% is recurring up from 56%, last year.
The operating profit decreased to £0.9m from £1.4m reflecting higher costs with a net debt of £1m compared to net cash of £1.1m. 


United Kingdom

Aptamer Group PLC operates as a biotechnology company. The Company focuses on the development of aptamer technologies and develops nucleic acid aptamers for use in research and development, biomarker discovery, diagnostics, and therapeutic developments. Aptamer Group serves customers in the United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aptamer Group (APTA LN)

Hybridan Small Cap Feast: 30/04/2025

The developer of next-generation synthetic binders delivering innovation to the life science industry has entered into a global licensing agreement...

Hybridan

Sosandar PLC - Hybridan Small Cap Feast: 14/10/2025

In addition to the Placing, the Company is providing existing eligible shareholders with the opportunity to subscribe for Retail Offer Shares at...

Hybridan

Hybridan Small Cap Feast: 13/10/2025

1Spatial Holdings 53.0p £60.87m (SPA.L) The global Location Master Data Management software and solutions provider reports Interims to July.

Hybridan

Xeros Technology Group Plc - Hybridan Small Cap Feast: 08/10/2025

The precision intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development, and...

Hybridan

Hybridan Small Cap Feast: 07/05/2025

1Spatial 44.5p £56.76m (SPA.L) The global Location Master Data Management software and solutions Company announces finals to January 2025.

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)